MarkWide Research

Sale!

Pulmonary Arterial Hypertension Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: October, 2022
No of Pages: 159
Delivery Format: PDF+Excel

$2,950.00

Pulmonary Arterial Hypertension (PAH) Market size exceeded USD 6.6 billion in 2020 and is anticipated to grow at a CAGR of 6% between 2021 and 2027. The strong product pipeline and novel drug combination awaiting approval are expected to boost the market growth. Furthermore, pulmonary arterial hypertension is a rare lung disorder that is commonly reported in children. The high proportion of children suffering from untreated PAH offers immense market expansion opportunities and is poised to promote the use of pulmonary arterial hypertension drugs.

However, side effects associated with the drugs may negatively influence the market progression. Vasodilators are widely prescribed for the treatment of patients with PAH to open blocked and narrowed blood vessels. Studies report that vasodilators have a number of side effects such as tachycardia, edema, heart palpitations, chest pain, etc. Owing to the substantial side effects associated with the use of vasodilators in chronically ill patients, the U.S. FDA regulates the use of this drug. Further, the PAH drugs that treat high blood pressure and dilate blood vessels require to submit reasonable assurance regarding the safety and effectiveness of the drugs. These drugs require the U.S. FDA approval before commercializing in the market. The FDA drug approval represents a complicated process that demonstrates the safety and efficacy of the drug. Hence, a time-consuming regulatory process and side effects related to the use of PAH drugs might hamper the industry growth during the forecast timeframe.
The pulmonary arterial hypertension market has been slightly impacted credited to the COVID-19 and the slender effects of the coronavirus pandemic may remain in the coming years. The impact of coronavirus outbreak on the industry peaked during early 2020 wherein, pulmonary arterial hypertension patients were at a higher risk of suffering from coronavirus. Other challenges including hindrance in diagnostic testing, changed guidelines pertaining to the hospital & emergency care, and interrupted drug supply chain among others had impeded the industry expansion. The pandemic has exhibited the importance of PAH drugs as a response to the increasing number of hospitalized PAH-COVID-19 patients.

Rising geriatric population globally will stimulate the industry progression

Rising geriatric population base in developing countries is positively influencing the market value. According to the United Nations report, in 2020, the aging population accounted for around 727 million people aged 65 years or above worldwide. This number is projected to grow in the coming decades by two-fold, reaching over 1.5 billion by 2050. As per the United Nations Population Fund and HelpAge India statistics, the number of elderly adults in India will reach to 173 million by 2026. Thus, with the significant proportion of population aging, the frequency of PAH in the elderly population will increase in the foreseeable future. Rising age is one of the non-modifiable factors that surges the risk related to PAH. Additionally, the elderly population base is prone to this disease due to diastolic dysfunction and age-associated blood vessel stiffening that further augments the business demand.
Several educational and awareness programs are initiated by market players and the government to increase the awareness level for PAH in healthcare providers and patients. These programs further prove beneficial for the elderly population base as it raises the awareness level amongst them. Several government organizations such as the WHO, Million Hearts, and others have undertaken certain initiatives to create awareness that accelerates the business revenue.

Growing demand for endothelin receptor antagonist is set to promote the pulmonary arterial hypertension market expansion

The endothelin receptor antagonist segment is predicted to witness 5.5% growth rate through 2027 owing to the rising demand for endothelin receptor antagonist drugs. These drugs are widely recommended as a targeted therapy to reverse the damage of the heart & lungs, slow the progression of PAH, and dilate blood vessels among others. The clinical studies have confirmed that patient with pulmonary arterial hypertension produces high amount of endothelin that often leads to high blood pressure. Thus, an endothelin receptor antagonist is highly prescribed by physicians to reduce the amount of endothelin present in the blood vessels. Moreover, progressive investments for research and development of endothelin receptor antagonist will promote the segment growth. Recently there has been a rapid expansion in research targeting endothelin receptor that has other therapeutic advantages, mainly in the treatment of pulmonary arterial hypertension.

Numerous advantages offered by oral drug administration is poised to impel the market growth

The oral segment in the pulmonary arterial hypertension market dominated more than 69% of the revenue share in 2020 led by the oral route of administration that offers a broad range of dosage forms such as tablets, capsules, and solutions among others. The oral route is the most preferred route for drug administration attributed to its benefits including the convenience of drug administration, patient compliance, and non-invasiveness. Oral therapies increase patient safety and comfort at an affordable cost. Furthermore, rapid delivery of drugs, a higher rate of bioavailability, and high efficacy among others will propel the segment revenue 

Increase in prevalence of pulmonary arterial hypertension in the North America region is slated to foster the regional growth

U.S. dominated the North America pulmonary arterial hypertension market and will reach USD 6.25 billion by 2027 driven by the numerous factors such as the availability of a high number of board-certified physicians, growing hospital admissions related to PAH, and growing supportive government initiatives among others. The prevalence of PAH is increasing in the country attributed to the risk factors comprising smoking, HIV, sedentary lifestyle, and alcohol consumption among others. In addition, in the U.S., the Orphan Drug Act (ODA) was introduced in 1983 to provide incentives for industry investment in treatments for PAH.
In Europe, Germany market held 10% of revenue share in 2020 and is predicted to cross USD 194 million by 2027 on account of the increase in the prevalence of pulmonary arterial hypertension, optimal health workforce, and facilitative government initiatives to improve the health of patients suffering from PAH in the country. As per the article published by the National Center for Biotechnology Information, in 2016, left heart disease is one of the common factors causing PAH that affected around 1.3 million people in Germany. According to the article published in 2020, over 5.6 million health workers were working in Germany. A large health workforce highlights well-developed healthcare infrastructure in the country. The German health care system covers over 80% of the medical costs of its residents is assisting the patients to avail the quality of treatment for pulmonary arterial hypertension.

Strategies adopted by prominent players are projected to spur the industry demand

Some of the major companies operating in the market are Bayer AG, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, and Johnson & Johnson among others. These major participants are adopting strategic formulations such as new product development & commercialization, commercial expansion, distribution agreements for business expansion. Moreover, these leaders are investing heavily in developing products, thereby fuelling the revenue generation.

Pulmonary arterial hypertension market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Drug Class, 2016 – 2027 (USD Million)

  • Prostacyclin And Prostacyclin Analogs
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Endothelin Receptor Antagonist (ERA)
  • Phosphodiesterase 5 (PDE-5)
  • Vasodilators
  • Others

Market, By Route of Administration, 2016 – 2027 (USD Million)

  • Oral
  • Intravenous
  • Inhalation

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Chapter 1   Methodology

1.1    Market definition

1.2    Base estimates & working

1.3    Forecast parameters

1.4    Data validation

1.5    Data sources

1.5.1    Secondary

1.5.1.1    Paid sources

1.5.1.2    Unpaid sources

1.5.2    Primary

Chapter 2   Executive Summary

2.1    Pulmonary arterial hypertension industry 3600 synopsis, 2016 – 2027

2.1.1    Business trends

2.1.2    Drug class trends

2.1.3    Route of administration trends

2.1.4    Regional trends

Chapter 3   Pulmonary Arterial Hypertension Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2016 – 2027 (USD Million)

3.3    Industry impact factors

3.3.1    Growth drivers

3.3.1.1    Increase in prevalence of pulmonary arterial hypertension

3.3.1.2    Strong product pipeline

3.3.1.3    Growing government initiatives

3.3.1.4    Rising global geriatric population

3.3.2    Industry pitfalls & challenges

3.3.2.1    Patent expiration

3.3.2.2    Side effects associated with the drugs

3.4    Growth potential analysis

3.4.1    By drug class

3.4.2    By route of administration

3.5    COVID-19 impact analysis

3.6    Porter’s analysis

3.7    Competitive landscape, 2020

3.7.1    Company matrix analysis, 2020

3.8    PESTEL analysis

Chapter 4   Pulmonary Arterial Hypertension Market, By Drug Class

4.1    Key segment trends

4.2    Prostacyclin and prostacyclin analogs

4.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.3    Soluble guanylate cyclase (SGC) stimulators

4.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.4    Endothelin receptor antagonist (ERA)

4.4.1    Market size, by region, 2016 – 2027 (USD Million)

4.5    Phosphodiesterase 5 (PDE-5)

4.5.1    Market size, by region, 2016 – 2027 (USD Million)

4.6    Vasodilators

4.6.1    Market size, by region, 2016 – 2027 (USD Million)

4.7    Others

4.7.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 5   Pulmonary Arterial Hypertension Market, By Drug Class

5.1    Key segment trends

5.2    Oral

5.2.1    Market size, by region, 2016 – 2027 (USD Million)

5.3    Intravenous

5.3.1    Market size, by region, 2016 – 2027 (USD Million)

5.4    Inhalation

5.4.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 6   Pulmonary Arterial Hypertension Market, By Region

6.1    Key regional trends

6.2    North America

6.2.1    Market size, by country, 2016 – 2027 (USD Million)

6.2.2    Market size, by drug class, 2016 – 2027 (USD Million)

6.2.3    Market size, by route of administration, 2016 – 2027 (USD Million)

6.2.4    U.S.

6.2.4.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.2.4.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.2.5    Canada

6.2.5.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.2.5.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3    Europe

6.3.1    Market size, by country, 2016 – 2027 (USD Million)

6.3.2    Market size, by drug class, 2016 – 2027 (USD Million)

6.3.3    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3.4    Germany

6.3.4.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.3.4.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3.5    UK

6.3.5.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.3.5.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3.6    France

6.3.6.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.3.6.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3.7    Spain

6.3.7.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.3.7.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3.8    Italy

6.3.8.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.3.8.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4    Asia Pacific

6.4.1    Market size, by country, 2016 – 2027 (USD Million)

6.4.2    Market size, by drug class, 2016 – 2027 (USD Million)

6.4.3    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4.4    Japan

6.4.4.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.4.4.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4.5    China

6.4.5.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.4.5.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4.6    India

6.4.6.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.4.6.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4.7    Australia

6.4.7.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.4.7.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4.8    South Korea

6.4.8.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.4.8.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.5    Latin America

6.5.1    Market size, by country, 2016 – 2027 (USD Million)

6.5.2    Market size, by drug class, 2016 – 2027 (USD Million)

6.5.3    Market size, by route of administration, 2016 – 2027 (USD Million)

6.5.4    Brazil

6.5.4.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.5.4.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.5.5    Mexico

6.5.5.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.5.5.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.5.6    Argentina

6.5.6.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.5.6.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.6    Middle East and Africa

6.6.1    Market size, by country, 2016 – 2027 (USD Million)

6.6.2    Market size, by drug class, 2016 – 2027 (USD Million)

6.6.3    Market size, by route of administration, 2016 – 2027 (USD Million)

6.6.4    South Africa

6.6.4.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.6.4.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.6.5    Saudi Arabia

6.6.5.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.6.5.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.6.6    UAE

6.6.6.1    Market size, by drug class, 2016 – 2027 (USD Million)

6.6.6.2    Market size, by route of administration, 2016 – 2027 (USD Million)

Chapter 7   Company Profiles

7.1    Competitive dashboard, 2020

7.2    Bayer AG

7.2.1    Business overview

7.2.2    Financial data

7.2.3    Product landscape

7.2.4    Strategic outlook

7.2.5    SWOT analysis

7.3    Eli Lilly and Company

7.3.1    Business overview

7.3.2    Financial data

7.3.3    Product landscape

7.3.4    Strategic outlook

7.3.5    SWOT analysis

7.4    Gilead Sciences, Inc.

7.4.1    Business overview

7.4.2    Financial data

7.4.3    Product landscape

7.4.4    Strategic outlook

7.4.5    SWOT analysis

7.5    GlaxoSmithKline plc.

7.5.1    Business overview

7.5.2    Financial data

7.5.3    Product landscape

7.5.4    Strategic outlook

7.5.5    SWOT analysis

7.6    Johnson & Johnson

7.6.1    Business overview

7.6.2    Financial data

7.6.3    Product landscape

7.6.4    Strategic outlook

7.6.5    SWOT analysis

7.7    Pfizer, Inc.

7.7.1    Business overview

7.7.2    Financial data

7.7.3    Product landscape

7.7.4    Strategic outlook

7.7.5    SWOT analysis

7.8    United Therapeutics Corporation

7.8.1    Business overview

7.8.2    Financial data

7.8.3    Product landscape

7.8.4    Strategic outlook

7.8.5    SWOT analysis

Data Tables

TABLE 1.    Pulmonary arterial hypertension industry 3600 synopsis, 2016-2027

TABLE 2.    Global pulmonary arterial hypertension market, 2016 – 2020 (USD Million)

TABLE 3.    Global pulmonary arterial hypertension market, 2021 – 2027 (USD Million)

TABLE 4.    Global pulmonary arterial hypertension market, by drug class, 2016 – 2020 (USD Million)

TABLE 5.    Global pulmonary arterial hypertension market, by drug class, 2021 – 2027 (USD Million)

TABLE 6.    Global pulmonary arterial hypertension market, by route of administration, 2016 – 2020 (USD Million)

TABLE 7.    Global pulmonary arterial hypertension market, by route of administration, 2021 – 2027 (USD Million)

TABLE 8.    Global pulmonary arterial hypertension market, by region, 2016 – 2020 (USD Million)

TABLE 9.    Global pulmonary arterial hypertension market, by region, 2021 – 2027 (USD Million)

TABLE 10.    Industry impact forces

TABLE 11.    Prostacyclin and prostacyclin analogs market size, by region, 2016 – 2020 (USD Million)

TABLE 12.    Prostacyclin and prostacyclin analogs market size, by region, 2021 – 2027 (USD Million)

TABLE 13.    Soluble guanylate cyclase (SGC) stimulators market size, by region, 2016 – 2020 (USD Million)

TABLE 14.    Soluble guanylate cyclase (SGC) stimulators market size, by region, 2021 – 2027 (USD Million)

TABLE 15.    Endothelin receptor antagonist (ERA) market size, by region, 2016 – 2020 (USD Million)

TABLE 16.    Endothelin receptor antagonist (ERA) market size, by region, 2021 – 2027 (USD Million)

TABLE 17.    Phosphodiesterase 5 (PDE-5) market size, by region, 2016 – 2020 (USD Million)

TABLE 18.    Phosphodiesterase 5 (PDE-5) market size, by region, 2021 – 2027 (USD Million)

TABLE 19.    Vasodilators market size, by region, 2016 – 2020 (USD Million)

TABLE 20.    Vasodilators market size, by region, 2021 – 2027 (USD Million)

TABLE 21.    Others market size, by region, 2016 – 2020 (USD Million)

TABLE 22.    Others market size, by region, 2021 – 2027 (USD Million)

TABLE 23.    Oral market size, by region, 2016 – 2020 (USD Million)

TABLE 24.    Oral market size, by region, 2021 – 2027 (USD Million)

TABLE 25.    Intravenous market size, by region, 2016 – 2020 (USD Million)

TABLE 26.    Intravenous market size, by region, 2021 – 2027 (USD Million)

TABLE 27.    Inhalation market size, by region, 2016 – 2020 (USD Million)

TABLE 28.    Inhalation market size, by region, 2021 – 2027 (USD Million)

TABLE 29.    North America pulmonary arterial hypertension market size, by country, 2016 – 2020 (USD Million)

TABLE 30.    North America pulmonary arterial hypertension market size, by country, 2021 – 2027 (USD Million)

TABLE 31.    North America pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 32.    North America pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 33.    North America pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 34.    North America pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 35.    U.S. pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 36.    U.S. pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 37.    U.S. pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 38.    U.S. pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 39.    Canada pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 40.    Canada pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 41.    Canada pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 42.    Canada pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 43.    Europe pulmonary arterial hypertension market size, by country, 2016 – 2020 (USD Million)

TABLE 44.    Europe pulmonary arterial hypertension market size, by country, 2021 – 2027 (USD Million)

TABLE 45.    Europe pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 46.    Europe pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 47.    Europe pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 48.    Europe pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 49.    Germany pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 50.    Germany pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 51.    Germany pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 52.    Germany pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 53.    UK pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 54.    UK pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 55.    UK pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 56.    UK pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 57.    France pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 58.    France pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 59.    France pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 60.    France pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 61.    Spain pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 62.    Spain pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 63.    Spain pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 64.    Spain pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 65.    Italy pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 66.    Italy pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 67.    Italy pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 68.    Italy pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 69.    Asia Pacific pulmonary arterial hypertension market size, by country, 2016 – 2020 (USD Million)

TABLE 70.    Asia Pacific pulmonary arterial hypertension market size, by country, 2021 – 2027 (USD Million)

TABLE 71.    Asia Pacific pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 72.    Asia Pacific pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 73.    Asia Pacific pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 74.    Asia Pacific pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 75.    Japan pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 76.    Japan pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 77.    Japan pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 78.    Japan pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 79.    China pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 80.    China pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 81.    China pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 82.    China pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 83.    India pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 84.    India pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 85.    India pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 86.    India pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 87.    Australia pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 88.    Australia pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 89.    Australia pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 90.    Australia pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 91.    South Korea pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 92.    South Korea pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 93.    South Korea pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 94.    South Korea pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 95.    Latin America pulmonary arterial hypertension market size, by country, 2016 – 2020 (USD Million)

TABLE 96.    Latin America pulmonary arterial hypertension market size, by country, 2021 – 2027 (USD Million)

TABLE 97.    Latin America pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 98.    Latin America pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 99.    Latin America pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 100.    Latin America pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 101.    Brazil pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 102.    Brazil pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 103.    Brazil pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 104.    Brazil pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 105.    Mexico pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 106.    Mexico pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 107.    Mexico pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 108.    Mexico pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 109.    Argentina pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 110.    Argentina pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 111.    Argentina pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 112.    Argentina pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 113.    MEA pulmonary arterial hypertension market size, by country, 2016 – 2020 (USD Million)

TABLE 114.    MEA pulmonary arterial hypertension market size, by country, 2021 – 2027 (USD Million)

TABLE 115.    MEA pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 116.    MEA pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 117.    MEA pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 118.    MEA pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 119.    South Africa pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 120.    South Africa pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 121.    South Africa pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 122.    South Africa pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 123.    Saudi Arabia pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 124.    Saudi Arabia pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 125.    Saudi Arabia pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 126.    Saudi Arabia pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 127.    UAE pulmonary arterial hypertension market size, by drug class, 2016 – 2020 (USD Million)

TABLE 128.    UAE pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 129.    UAE pulmonary arterial hypertension market size, by route of administration, 2016 – 2020 (USD Million)

TABLE 130.    UAE pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)
Charts & Figures

FIG. 1    Market estimation and forecast methodology

FIG. 2    Top-down approach

FIG. 3    Industry segmentation

FIG. 4    Global pulmonary arterial hypertension market size, 2016 – 2027 (USD Million)

FIG. 5    Growth potential analysis, by drug class

FIG. 6    Growth potential analysis, by route of administration

FIG. 7    Porter’s analysis

FIG. 8    Competitive matrix analysis

FIG. 9    PESTEL analysis

FIG. 10    Key segment trends, by drug class

FIG. 11    Key segment trends, by route of administration

FIG. 12    Key regional trends

FIG. 13    Competitive dashboard, 2020

Market, By Drug Class, 2016 – 2027 (USD Million)

  • Prostacyclin And Prostacyclin Analogs
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Endothelin Receptor Antagonist (ERA)
  • Phosphodiesterase 5 (PDE-5)
  • Vasodilators
  • Others

Market, By Route of Administration, 2016 – 2027 (USD Million)

  • Oral
  • Intravenous
  • Inhalation

Bayer AG, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, and Johnson & Johnson among others.

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF